Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply
- PMID: 34217393
- DOI: 10.1016/S0140-6736(21)00374-3
Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply
Conflict of interest statement
A summary of competing interests in available in the appendix.
Comment on
-
Pembrolizumab plus chemotherapy in triple-negative breast cancer.Lancet. 2021 Jul 3;398(10294):24. doi: 10.1016/S0140-6736(21)00380-9. Lancet. 2021. PMID: 34217392 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources